XENE Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -- compared to Xenon Pharmaceuticals's net margin of --. Xenon Pharmaceuticals's return on equity of -- beat Edesa Biotech's return on equity of --.

Xenon Pharmaceuticals has a consensus price target of $57.81, signalling upside risk potential of 62.94%. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 698.32%. Given that Edesa Biotech has higher upside potential than Xenon Pharmaceuticals, analysts believe Edesa Biotech is more attractive than Xenon Pharmaceuticals.

Xenon Pharmaceuticals has a beta of 1.262, which suggesting that the stock is 26.226% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.279%.

Xenon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Xenon Pharmaceuticals quarterly revenues are --, which are smaller than Edesa Biotech quarterly revenues of --. Xenon Pharmaceuticals's net income of -$65.7M is lower than Edesa Biotech's net income of -$1.6M. Notably, Xenon Pharmaceuticals's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals is 209.83x versus 23.54x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -- compared to Xenon Pharmaceuticals's net margin of --. Xenon Pharmaceuticals's return on equity of -- beat ESSA Pharma's return on equity of --.

Xenon Pharmaceuticals has a consensus price target of $57.81, signalling upside risk potential of 62.94%. On the other hand ESSA Pharma has an analysts' consensus of $11.61 which suggests that it could grow by 612.23%. Given that ESSA Pharma has higher upside potential than Xenon Pharmaceuticals, analysts believe ESSA Pharma is more attractive than Xenon Pharmaceuticals.

Xenon Pharmaceuticals has a beta of 1.262, which suggesting that the stock is 26.226% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.362%.

Xenon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Xenon Pharmaceuticals quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. Xenon Pharmaceuticals's net income of -$65.7M is lower than ESSA Pharma's net income of -$8.5M. Notably, Xenon Pharmaceuticals's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals is 209.83x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

ImmunoPrecise Antibodies has a net margin of -- compared to Xenon Pharmaceuticals's net margin of -41.68%. Xenon Pharmaceuticals's return on equity of -- beat ImmunoPrecise Antibodies's return on equity of -68.99%.

Xenon Pharmaceuticals has a consensus price target of $57.81, signalling upside risk potential of 62.94%. On the other hand ImmunoPrecise Antibodies has an analysts' consensus of $5.00 which suggests that it could grow by 1134.57%. Given that ImmunoPrecise Antibodies has higher upside potential than Xenon Pharmaceuticals, analysts believe ImmunoPrecise Antibodies is more attractive than Xenon Pharmaceuticals.

Xenon Pharmaceuticals has a beta of 1.262, which suggesting that the stock is 26.226% more volatile than S&P 500. In comparison ImmunoPrecise Antibodies has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.679%.

Xenon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunoPrecise Antibodies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals pays -- of its earnings as a dividend. ImmunoPrecise Antibodies pays out -- of its earnings as a dividend.

Xenon Pharmaceuticals quarterly revenues are --, which are smaller than ImmunoPrecise Antibodies quarterly revenues of $4.5M. Xenon Pharmaceuticals's net income of -$65.7M is lower than ImmunoPrecise Antibodies's net income of -$1.9M. Notably, Xenon Pharmaceuticals's price-to-earnings ratio is -- while ImmunoPrecise Antibodies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals is 209.83x versus 0.62x for ImmunoPrecise Antibodies. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -- compared to Xenon Pharmaceuticals's net margin of -1470.02%. Xenon Pharmaceuticals's return on equity of -- beat Lexaria Bioscience's return on equity of -100.77%.

Xenon Pharmaceuticals has a consensus price target of $57.81, signalling upside risk potential of 62.94%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.50 which suggests that it could grow by 468.18%. Given that Lexaria Bioscience has higher upside potential than Xenon Pharmaceuticals, analysts believe Lexaria Bioscience is more attractive than Xenon Pharmaceuticals.

Xenon Pharmaceuticals has a beta of 1.262, which suggesting that the stock is 26.226% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.482%.

Xenon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenon Pharmaceuticals pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Xenon Pharmaceuticals quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $183.9K. Xenon Pharmaceuticals's net income of -$65.7M is lower than Lexaria Bioscience's net income of -$2.7M. Notably, Xenon Pharmaceuticals's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenon Pharmaceuticals is 209.83x versus 37.85x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.